SCHEMBL4177914

SCHEMBL4177914

Cc1cc(Oc2cc[c]cc2)nc(N)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.63
RAB9A P51151 3/20 0.63
NPC1 O15118 2/20 0.63
POLB P06746 1/20 0.47
NUDT1 P36639 3/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
MAPT P10636 4/20 0.44
CYP1A2 P05177 3/20 0.44
CYP2C19 P33261 3/20 0.44
MAPK1 P28482 3/20 0.44
CYP2C9 P11712 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HPGD P15428 1/20 0.44
ATM Q13315 1/20 0.44
HTT P42858 1/20 0.43
ALDH1A1 P00352 2/20 0.41
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4528068 0.83 NPC1 (0.67) SMN1; SMN2RAB9ANPC1POLBNUDT1
SCHEMBL7363505 0.80 SMN1; SMN2 (0.62) SMN1; SMN2RAB9ANPC1POLBNUDT1
SCHEMBL4528036 0.78 SMN1; SMN2 (0.64) SMN1; SMN2RAB9ANPC1NUDT1KMT2A
SCHEMBL2902967 0.73 HTT (0.53) SMN1; SMN2POLBKMT2AMEN1MAPT
SCHEMBL4535234 0.72 CYP1A2 (0.57) SMN1; SMN2RAB9ANPC1NUDT1KMT2A
SCHEMBL754480 0.70 NUDT1 (0.61) SMN1; SMN2RAB9ANPC1POLBNUDT1
SCHEMBL11972460 0.69 F10 (0.58) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL10720328 0.69 RAB9A (0.54) SMN1; SMN2RAB9ANPC1POLBNUDT1
SCHEMBL21186284 0.69 SMN1; SMN2 (0.54) SMN1; SMN2RAB9ANPC1POLBKMT2A
SCHEMBL2334140 0.69 IGF1R (0.40) RAB9ANPC1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082404-A1 BENZIMIDAZOLES MERCK PATENT GMBH (DE) 2009-03-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082404-A1 BENZIMIDAZOLES TIE1, KDR, FLT1 SMN1; SMN2 2539/4885RAB9A 3539/4885NPC1 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.